Skip to main content

Table 1 Study characteristics

From: Does hydroxyapatite coating have no advantage over porous coating in primary total hip arthroplasty? A meta-analysis

Study

Study design

Sample size (HA/control)

Mean ages of patients (years)

Sex distribution (female/male)

Inclusion criteria

Camazzola et al. [28]

RCT

61 (34/27)

48.2 ± 9.0/50.4 ± 8.7

22/39

Men younger than 60 years and women younger than 65 years having elective primary THA

Dorr et al. [16]

Retrospective, matched pair

30 (15/15)

55 (38–71)

10/5

Patients who underwent bilateral primary THA

Hamadouche et al. [34]

RCT

45 (22/23)

65/64

41/39

Patients with osteoarthritis of the hip requiring THA

Incavo et al. [32]

RCT

50 (24/26)

55

NR

Patients who underwent THA

Kim et al. [23]

RCT

100 (50/50)

45.3 (27–61)

14/36

Patients who underwent sequential bilateral primary THA

Kim et al. [24]

RCT

110 (55/55)

46.3 (27–63)

39/16

Patients who underwent bilateral primary THA

Lee and Lee 2007 [33]

RCT

40 (20/20)

44 (25–72)

2/18

Patients who had late-stage bilateral osteonecrosis were randomly treated with bilateral THA

Lombardi Jr. et al. [12]

Retrospective, observational study

131 (46/85)

52 (29–72)/51 (22–78)

67/97

Patients who underwent THA using a MHP

Mcpherson et al. [36]

Retrospective, matched pair

84 (42/42)

55 ± 11.4/56.5 ± 11.7

36/48

Patients of the same gender, bone type, activity level, and diagnosis, ages within 5 years, weight within 25 pounds, Charnley activity class

Parvizi et al. [9]

Prospective, matched-pair

86 (43/43)

66.8 ± 6.2/65.7 ± 5.9

NR

The patients matched for age, sex, weight, diagnosis, Charnley class, operative approach, bone quality, femoral head size, type of acetabular component, and duration of follow-up

Paulsen et al. [38]

Retrospective comparison

3,158/4,749

NR

3,834/4,073

Patients underwent primary uncemented THA, who were younger than 70 years of age at surgery

Ranawat et al. [35]

RCT

174 (92/82)

54.9 (29.4–67.5)/55.5 (28.6–71.8)

38/114

Patients received cementless THA with the Ranawat-Burstein metaphyseal-diaphyseal fit hip system

Rothman et al. [10]

Retrospective, matched pair

104 (52/52)

64 (31.2–86.1)

49/49

Consecutive THA with use of Taperloc stem, matched for age, sex, weight, diagnosis, Charnley class, operative approach, and duration of follow-up

Sanchez-Sotelo et al. [37]

Retrospective, matched-pair

136 (68/68)

54 (23–66)/56 (22–67)

56/80

Patients who had a primary hip replacement with insertion of either a porous-coated or HA-coated Omniflex femoral componene

Sano et al. [39]

Retrospective, observational study

55 (24/31)

64.0 (51–83)/62.7 (41–80)

49/3

Patients in whom surgery was performed at least 2 years before the present study

Santori et al. [14]

Retrospective, observational study

227 (158/69)

NR

NR

Patients underwent THA with the anatomic prosthesis

Søballe et al. [4]

RCT

26 (14/12)

56.8 (48–63)/58.6 (50–68)

NR

Patients who underwent THR to receive prosthetic with either Ti-alloy coating or HA coating

Tanzer et al. [22]

RCT

39 (17/22)

66 (54–80)/64 (43–78)

13/26

Patients undergoing a cementless THA

Tanzer et al. [31]

RCT

318 (164/154)

64.5 ± 9.9/63.1 ± 10.5

153/165

All patients who underwent cementless THA

Yee et al. [30]

RCT

62 (35/27)

48.2 ± 9.0/50.4 ± 8.7

11/22

Men younger than 60 years of age and women younger than 65 years of age undergoing primary THA

Yoon et al. [29]

RCT

75 (37/38)

45.3 (20–69)/46.0 (23–71)

14/49

Patients who underwent THA use a multilock femoral stem with or without HA/TCP coating

  1. RCT randomized controlled trials, HA hydroxyapatite, NR not reported, THA total hip arthroplasty, TCP tricalcium phosphate.